{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.05268","value":"0.1048"},{"groupId":"OG002","spread":"0.00894","value":"0.0516"},{"comment":"Standard deviation could not be calculated as only one participant was analyzed.","groupId":"OG003","spread":"NA","value":"0.0362"},{"comment":"Standard deviation could not be calculated as only one participant was analyzed.","groupId":"OG004","spread":"NA","value":"0.0488"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be calculated as only one participant was analyzed.","groupId":"OG001","spread":"NA","value":"0.1060"},{"comment":"Standard deviation could not be calculated as only one participant was analyzed.","groupId":"OG002","spread":"NA","value":"0.0396"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received MORAb-066 0.1 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG000","title":"MORAb-066 0.1 mg/kg"},{"description":"Participants received MORAb-066 0.3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG001","title":"MORAb-066 0.3 mg/kg"},{"description":"Participants received MORAb-066 1 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG002","title":"MORAb-066 1 mg/kg"},{"description":"Participants received MORAb-066 2 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG003","title":"MORAb-066 2 mg/kg"},{"description":"Participants received MORAb-066 3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG004","title":"MORAb-066 3 mg/kg"}],"paramType":"MEAN","populationDescription":"The PK analysis set was the group of participants who had sufficient PK data to derive at least one PK parameter. Here, \"Overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure. Here, \"Number analyzed\" signifies participants evaluable at a given time points for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 1 and 22: 0-168 hours post-dose (Cycle length=28 days)","title":"CL: Total Body Clearance for MORAb-066","type":"SECONDARY","unitOfMeasure":"liter per hour"}